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OBJECTIVES We sought to evaluate the effects of spironolactone on cardiac sympathetic nerve activity and
left ventricular (LV) remodeling in patients with dilated cardiomyopathy (DCM).
BACKGROUND Aldosterone prevents the uptake of norepinephrine and promotes structural remodeling of the
heart. Spironolactone, an aldosterone receptor blocker, improves LV remodeling in patients
with DCM, but its influence on cardiac sympathetic nerve activity has not been determined.
METHODS We selected 30 patients with DCM who were treated with an angiotensin-converting enzyme
inhibitor and a loop diuretic. Fifteen patients were assigned to receive spironolactone
additionally, whereas the remaining 15 patients continued their current regimen. The delayed
heart/mediastinum (H/M) count ratio, delayed total defect score (TDS), and washout rate
(WR) were determined from iodine-123 (123I)-meta-iodobenzylguanidine (MIBG) images
before and six months after treatment. The left ventricular end-diastolic volume (LVEDV)
and left ventricular ejection fraction (LVEF) were determined by echocardiography, and New
York Heart Association (NYHA) functional class was estimated.
RESULTS In the spironolactone group, the TDS decreased from 36  9 to 24  13 (p  0.0001), the
H/M ratio increased from 1.64 0.20 to 1.86 0.27 (p 0.0001), and WR decreased from
55  12% to 41  15% (p  0.0005). In addition, the LVEDV decreased from 187  26
to 154  41 ml (p  0.005), and LVEF increased from 33  6% to 39  6% (p  0.005).
However, there were no significant changes in these parameters in the control group. There
was a significant correlation between changes in the 123I-MIBG findings and changes in
LVEDV with spironolactone treatment (TDS: r  0.684, p  0.0038; H/M ratio: r 
0.878, p  0.0001; and WR: r  0.737, p  0.0011). The NYHA functional class
improved in both groups but showed a greater improvement in the spironolactone group than
in the control group (p  0.01).
CONCLUSIONS Spironolactone improves cardiac sympathetic nerve activity and LV remodeling in patients
with DCM. (J Am Coll Cardiol 2003;41:574–81) © 2003 by the American College of
Cardiology Foundation
Since the Randomized ALdactone Evaluation Study
(RALES) (1) reported the effectiveness of spironolactone in
the treatment of patients with congestive heart failure
(CHF), this drug has often been used in patients with severe
CHF. Aldosterone plays an important role in the patho-
physiology of CHF (2–5). Aldosterone promotes retention
of sodium, loss of magnesium and potassium, myocardial
and vascular fibrosis, baroreceptor dysfunction, vascular
damage and arterial noncompliance, structural remodeling,
sympathetic activation, and parasympathetic inhibition (5–
9). RALES reported that the addition of spironolactone (an
aldosterone receptor blocker) reduces the risk of death from
cardiac causes among patients who have severe left ventric-
ular (LV) systolic dysfunction and who are receiving stan-
dard therapy, including an angiotensin-converting enzyme
(ACE) inhibitor. Spironolactone also improves the symp-
toms of heart failure, as measured by changes in the New
York Heart Association (NYHA) functional class.
Myocardial imaging with iodine-123 (123I)-meta-
iodobenzylguanidine (MIBG), an analogue of norepineph-
rine, is a useful tool for detecting abnormalities of the
myocardial adrenergic nervous system in patients with
dilated cardiomyopathy (DCM) (10–14). A correlation
between the myocardial norepinephrine concentration and
123I-MIBG uptake in patients with DCM has been re-
ported (12). However, there are no reports on cardiac
123I-MIBG scintigraphic changes in response to long-term
spironolactone therapy in patients with DCM. However,
spironolactone is reported to improve LV remodeling in
patients with DCM (15).
In the present study, we evaluated whether spironolac-
tone improves cardiac sympathetic nerve activity and LV
remodeling in patients with DCM.
METHODS
Patients. Thirty patients (17 men and 13 women; age 65
15 years [range 40 to 84]) with DCM were included in the
study. A detailed history and physical examination, chest
radiography, standard electrocardiography, echocardiogra-
phy, thallium-201 and 123I-MIBG scintigraphy, coronary
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angiography, and left ventriculography were performed in
all patients. Patients with acute or chronic myocarditis,
previous myocardial infarction, coronary artery disease, or
valvular disease were excluded from the study. Patients were
in NYHA functional class II or III. All patients were being
treated with an ACE inhibitor and a loop diuretic. Treat-
ment with digitalis and vasodilators was allowed, but the use
of potassium-sparing diuretics was not permitted. The study
was approved by the Ethics Review Board of our institution,
and written, informed consent was obtained from all pa-
tients.
Study protocol. Fifteen patients were randomized to re-
ceive spironolactone additionally (25 mg/day), and the
remaining 15 patients continued their current drug regimen.
We performed a series of examinations before and six
months after treatment. In this study, no patients received
beta-blockers.
Cardiac 123I-MIBG scintigraphy. The 123I-MIBG scin-
tigram was obtained commercially (Daiichi-Radioisotope
Laboratories, Tokyo, Japan). Patients were injected intra-
venously with 123I-MIBG (111 MBq) while in an upright
position. Anterior planar and single-photon emission com-
puted tomographic (SPECT) images were acquired 15 min
after injection and repeated 4 h later. SPECT imaging was
performed with a dedicated single-headed imaging system
(Millennium MPR, GE Medical Systems, Waukesha, Wis-
consin). The energy, uniformity, and linearity were contin-
uously corrected. Images were acquired for 40 s each at 32
steps over a 180° orbit and were recorded at a digital
resolution of 128  128 pixels from the anterior planar
123I-MIBG image.
The heart/mediastinum count (H/M) ratio was deter-
mined from anterior planar delayed 123I-MIBG images
(Fig. 1). The washout rate (WR) was calculated by the
following formula: ([H  M]early  [H  M]delayed)/
(H  M)early  100 (%), where H  mean count/pixel in
the left ventricle; and M  mean count/pixel in the upper
mediastinum. In our laboratory, the normal value for the
delayed H/M ratio is 2.00 to 2.80, and the normal WR
value is 22% to 32%.
The myocardial delayed SPECT images for each patient
were divided into 20 segments (Fig. 2). The short-axis
images at the basal, middle, and apical ventricular levels
were divided into six segments. The apical segment of the
vertical long-axis image was divided into two segments.
Regional tracer uptake was assessed semiquantitatively using
a 4-point scoring system (0  normal uptake; 1  mildly
reduced uptake; 2  moderately reduced uptake; 3 
severely reduced uptake). The total defect score (TDS) was
calculated as the sum of the scores for all 20 segments.
Interobserver variability was determined in a blinded man-
ner by two independent observers. The interobserver corre-
lation was represented by r  0.90 (p  0.001).
Echocardiography. Echocardiographic measurements
were performed using standard methods in a blinded man-
ner before and six months after treatment. Left ventricular
end-diastolic volume (LVEDV) and left ventricular ejection
fraction (LVEF) were calculated by using the modified
Simpson method (16).
Statistical analysis. Statistical analysis was performed us-
ing Statview for Macintosh (Abacus Concepts, Berkeley,
California). Numeric results are expressed as the mean 
SD. The differences between continuous variables were
evaluated using a paired t test. Changes in NYHA func-
tional class were assessed using the Wilcoxon matched-
pairs, singed-rank test. Linear regression analysis was used
to determine the relationship between continuous variables.
A value of p  0.05 was considered statistically significant.
RESULTS
Clinical characteristics. There were no significant differ-
ences in the hemodynamic characteristics of the two groups.
Before treatment, the TDS, H/M ratio, WR, LVEDV,
LVEF, and NYHA functional class were similar in both
groups (Table 1).
Comparison of cardiac 123I-MIBG scintigraphic findings
before and after treatment. The TDS, H/M ratio, and
WR are summarized in Table 2. In the spironolactone
group, the TDS decreased significantly after six months
(24  13) from the baseline value (36  9; p  0.0001). In
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CHF  congestive heart failure
DCM  dilated cardiomyopathy
H/M  heart/mediastinum count
LV  left ventricular
LVEDV  left ventricular end-diastolic volume
LVEF  left ventricular ejection fraction
MIBG  meta-iodobenzylguanidine
NYHA  New York Heart Association
SPECT  single-photon emission computed
tomography
TDS  total defect score
WR  washout rate Figure 1. Cardiac
123I-MIBG uptake was quantified as the H/M ratio 4 h
after injection, using regions of interest positioned over the heart (H) and
upper mediastinum (M).
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contrast, in the control group, there was no significant
difference between the baseline TDS and that after six
months of treatment. Furthermore, after six months of
treatment, the TDS in the spironolactone group was sig-
nificantly lower than that in the control group (p  0.01).
Although uptake tended to improve in the inferior wall, the
difference was not significant. In the spironolactone group,
the H/M ratio increased significantly after six months (1.86
 0.27), compared with baseline (1.64 0.20; p 0.0001).
In contrast, in the control group, there were no significant
differences between the value at baseline and that after six
months of treatment. Furthermore, after six months of
treatment, the H/M ratio in the spironolactone group was
significantly higher than that in the control group (p 
0.05). In the spironolactone group, the WR decreased
significantly after six months (41  15%), compared with
baseline (55 12%; p 0.0005). In contrast, in the control
group, there were no significant differences between values
at baseline and after six months of treatment. Furthermore,
after six months of treatment, the WR in the spironolactone
group was significantly lower than that in the control group
(p  0.05).
Comparison of echocardiographic findings before and
after treatment. The changes in LVEDV and LVEF are
summarized in Table 3. In the spironolactone group, the
LVEDV decreased significantly after six months (154  41
ml), compared with the baseline value (187  26 ml; p 
0.005). In contrast, in the control group, there were no
significant differences between values at baseline and after
six months of treatment. Furthermore, after six months of
treatment, the LVEDV in the spironolactone group was
significantly lower than that in the control group (p 0.05).
In the spironolactone group, the LVEF increased signifi-
cantly after six months (39  6%), compared with baseline
(33  6%; p  0.005). In contrast, in the control group,
there were no significant differences between values at
baseline and after six months of treatment. Furthermore,
after six months of treatment, the LVEF in the spironolac-
tone group was significantly higher than that in the control
group (p  0.05).
Comparison of NYHA functional class before and after
treatment. The NYHA functional classes of the patients
are summarized in Table 3 and Figure 3. Patients in both
groups showed improvement after six months of treatment,
compared with baseline values (in the spironolactone group,
NYHA class from 2.8  0.4 to 1.7  0.5 [p  0.0005]; in
the control group, from 2.8  0.4 to 2.3  0.7 [p  0.05]).
After treatment, the NYHA functional class of patients in
the spironolactone group was better than that in the control
group (p  0.01).
Relationship between LVEDV and 123I-MIBG scinti-
graphic findings before and after treatment. There was a
significant correlation between changes in the 123I-MIBG
scintigraphic findings and changes in the LVEDV (Fig. 4)
with spironolactone treatment (TDS: r  0.684, p 
0.0038; H/M ratio: r  0.878, p  0.0001; and WR: r 
0.737, p  0.0011). In contrast, there was no relationship
between these parameters in the control group.
Figure 2. Segmentation scheme used to quantitate regional 123I-MIBG uptake.
Table 1. Clinical Characteristics of Patients in the






(n  15) p Value
Age (years) 66  15 65  16 NS
Gender (male/female) 8/7 9/6 NS
123I-MIBG
TDS 36  9 34  11 NS
H/M ratio 1.64  0.20 1.65  0.20 NS
WR (%) 55  12 50  10 NS
LVEDV (ml) 187  26 186  26 NS
LVEF (%) 33  6 31  8 NS
NYHA functional class NS
II 3 3
III 12 12
Data are presented as the mean value  SD.
H/M  heart/mediastinum count; LVEDV  left ventricular end-diastolic
volume; LVEF left ventricular ejection fraction; MIBG meta-iodobenzylguanidine;
NYHA  New York Heart Association; TDS  total defect score; WR  washout
rate.
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DISCUSSION
Aldosterone causes myocardial and vascular fibrosis (17,18),
direct vascular damage (9), and baroreceptor dysfunction by
altering Na, K-ATPase activity (7) and preventing myocar-
dial uptake of norepinephrine (5,19). A large proportion of
the low basal uptake of norepinephrine is probably due to
the loss of neuronal norepinephrine uptake in the failing
myocardium. However, some of the reduction in norepi-
nephrine uptake appears to be functional and reversible and
is mediated by hormonal factors, such as aldosterone.
Struthers et al. (5,19) reported that once norepinephrine is
taken up into cardiac cells, it is rapidly metabolized and
inactivated so that uptake is equivalent to the local disposal
in the myocardium.
The RALES investigators (1) reported that spironolac-
tone reduces the risk of cardiac death in patients with CHF.
Spironolactone may prevent myocardial fibrosis by blocking
the effect of aldosterone. Based on the RALES trial,
Zannad et al. (20) reported that adding spironolactone to an
ACE inhibitor decreases the concentrations of several
markers of cardiac fibrosis in patients with CHF. Myocar-
dial fibrosis may predispose patients to alterations in the
ventricular conduction time and therefore also to the devel-
opment of reentrant ventricular arrhythmias (19,21–23).
Spironolactone may also prevent sudden death by increasing
the myocardial uptake of norepinephrine (1). Myocardial
uptake of norepinephrine has been shown to be a strong
prognostic marker for overall mortality in CHF (13). Barr et
al. (5) reported that spironolactone increases cardiac neuro-
nal uptake of 123I-MIBG in patients with CHF. However,
that study included a small number of patients and the
observation period was relatively short, and all patients had
CHF caused by coronary artery disease. Therefore, in this
study, we examined whether long-term spironolactone ther-
apy improves cardiac sympathetic nerve activity by using
123I-MIBG imaging in patients with DCM.
Table 2. Changes in Total Defect Score, H/M Ratio, and WR for 123I-MIBG Imaging in
Patients With Dilated Cardiomyopathy
Patient
No.
TDS H/M Ratio WR (%)
Baseline 6 Months Baseline 6 Months Baseline 6 Months
Spironolactone group
1 20 6 1.98 2.09 42 39
2 40 48 1.42 1.39 75 76
3 45 32 1.38 1.53 47 50
4 34 12 1.74 1.94 44 24
5 40 23 1.57 1.92 50 26
6 30 18 1.76 2.1 46 28
7 30 9 1.88 2.43 51 34
8 32 21 1.91 2.06 51 40
9 22 8 1.62 1.97 55 29
10 32 21 1.84 1.91 39 38
11 37 32 1.6 1.63 63 55
12 41 29 1.57 1.74 55 44
13 41 25 1.48 1.76 70 40
14 48 29 1.52 1.86 58 28
15 50 45 1.36 1.54 78 66
Mean  SD 36  9 24  13*† 1.64  0.20 1.86  0.27*‡ 55  12 41  15‡§
Control group
1 41 36 1.48 1.65 48 59
2 21 31 1.77 1.62 49 58
3 23 33 1.72 1.66 51 55
4 27 33 1.84 1.69 54 52
5 40 36 1.64 1.58 60 58
6 41 43 1.63 1.63 46 45
7 17 24 1.7 1.75 36 41
8 38 50 1.28 1.32 63 72
9 43 46 1.37 1.41 65 62
10 44 30 1.86 1.76 38 50
11 20 22 1.86 1.68 34 50
12 40 38 1.82 1.97 58 42
13 24 23 1.51 1.51 60 62
14 50 44 1.42 1.68 50 44
15 38 51 1.87 1.58 41 45
Mean  SD 34  11 36  9 1.65  0.20 1.63  0.15 50  10 53  9
*p  0.0001 vs. baseline. †p  0.01 vs. control group. ‡p  0.05 vs. control group. §p  0.0005 vs. baseline.
H/M  heart/mediastinum count; TDS  total defect score; WR  washout rate.
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Iodine-123–MIBG, an analogue of the adrenergic
neuron-blocking agent guanethidine, is thought to utilize
the same mechanism of myocardial uptake and release as
norepinephrine (24). The myocardial norepinephrine con-
centration and 123I-MIBG uptake are correlated in patients
with DCM (12). Therefore, cardiac 123I-MIBG imaging is
a useful tool for detecting abnormalities of the myocardial
adrenergic nervous system in patients with DCM (10–14).
Several reports have suggested that the treatment of heart
failure can improve cardiac sympathetic nerve activity, based
on cardiac 123I-MIBG scintigraphic studies in patients with
DCM (25–30). In this study, the TDS, H/M ratio, and
WR, as determined by cardiac 123I-MIBG scintigraphy,
improved in the spironolactone treatment group compared
with the control group. Therefore, spironolactone may
mediate its effect by increasing myocardial uptake of nor-
epinephrine.
Tsutamoto et al. (15) reported that spironolactone im-
proves cardiac function and LV remodeling in patients with
mild to moderate nonischemic CHF. Moreover, cardiac
sympathetic nerve activity and cardiac function are corre-
lated in patients with DCM (31). In this study, spironolac-
tone improved LV volume and cardiac function, as well as
123I-MIBG uptake in patients with DCM. The reduction
of LV volume may have been due to blocking of the
mineralocorticoid receptor, which is known to be expressed
in the human heart (32,33). However, with respect to the
effect of spironolactone treatment in patients with DCM, it
is not known whether the reduction in LV volume (due to
the antiproliferative/antifibrotic effect of spironolactone)
increases the myocardial uptake of norepinephrine or
whether increasing the myocardial uptake of norepinephrine
causes a reduction in LV volume. Further studies are
necessary to clarify the relationship between the reduction in
LV volume and the increase in myocardial uptake of
norepinephrine.




LVEDV (ml) LVEF (%) NYHA Class
Baseline 6 Months Baseline 6 Months Baseline 6 Months
Spironolactone group
1 216 225 40 38 3 2
2 168 188 33 32 3 2
3 188 166 38 36 3 2
4 240 198 31 32 2 1
5 225 162 32 32 3 2
6 168 110 38 52 3 1
7 176 82 32 41 3 2
8 162 163 24 36 3 2
9 182 152 36 42 2 1
10 166 154 38 45 3 1
11 188 164 31 42 2 1
12 224 204 40 46 3 2
13 161 102 18 36 3 2
14 184 108 32 44 3 2
15 160 130 32 32 3 2
Mean  SD 187  26 154  41*† 33  6 39  6*† 2.8  0.4 1.7  0.5‡
Control group
1 184 186 30 35 3 3
2 188 224 28 26 3 3
3 250 215 40 48 3 3
4 166 175 40 36 2 2
5 166 175 36 28 3 1
6 169 207 40 39 3 2
7 168 156 31 38 3 2
8 165 162 24 28 3 3
9 236 250 19 15 3 3
10 186 203 32 34 2 1
11 169 122 40 45 3 2
12 182 186 38 37 2 2
13 166 146 24 22 3 2
14 183 161 26 30 3 3
15 208 186 15 33 3 3
Mean  SD 186  26 184  33 31  8 33  9 2.8  0.4 2.3  0.7§
*p  0.005 vs. baseline. †p  0.05 vs. control group. ‡p  0.0005 vs. baseline. §p  0.05 vs. baseline.
LVEDV  left ventricular end-diastolic volume; LVEF  left ventricular ejection fraction; NYHA  New York Heart
Association.
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In this study, delayed MIBG images were used to
determine the TDS and H/M ratio. There are two types of
norepinephrine and MIBG uptake: uptake-1 (neuronal
uptake), which occurs even if the concentration of norepi-
nephrine or MIBG is low, is dependent on sodium and
ATP and is suppressed by tricyclic antidepressants;
uptake-2 (extraneuronal uptake), which takes place only
when the norepinephrine or MIBG concentration is high,
occurs by diffusion and is unaffected by tricyclic agents
(34–36). Early imaging detects both uptake-1 and uptake-2
(37,38), whereas delayed imaging involves less uptake-2 and
therefore primarily reflects the status of cardiac sympathetic
nerve activity. For these reasons, we used delayed MIBG
imaging in this study. Previous reports suggest that WR is
the most clinically useful parameter for assessing the severity
and improvement of CHF (39,40). Increased norepineph-
rine turnover in cardiac sympathetic nerve endings may
decrease the uptake in delayed images, such that the increase
in turnover (i.e., increase in WR) reflects the severity of
CHF. In this study, all three parameters (delayed TDS,
delayed H/M ratio, and WR) improved with spironolactone
therapy. We hypothesize that one mechanism responsible
Figure 3. Changes in New York Heart Association (NYHA) functional class during treatment in the two groups.
Figure 4. Correlation between the changes in the 123I-MIBG scintigraphic findings and changes in left ventricular end-diastolic volume (LVEDV) after
six months of spironolactone treatment in 15 patients with dilated cardiomyopathy. Delta LVEDV  LVEDV value after six months  pretreatment value of
LVEDV; delta TDS  total defect score (TDS) value after six months  pretreatment value of TDS; delta H/M ratio  H/M ratio after six months 
pretreatment value of H/M ratio; delta WR  washout rate (WR) value after six months  pretreatment value of WR.
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for functional improvement in patients with DCM is
increased myocardial uptake of norepinephrine mediated by
spironolactone.
Study limitations. The small number of patients with
DCM included in this study was a limitation. In addition,
the present study employed a fixed spironolactone dose of
25 mg/day. The dose-response effects of spironolactone on
MIBG scintigraphic findings and LV remodeling must be
evaluated in future studies.
It is known that spironolactone therapy increases the
plasma aldosterone concentration (5,15). It has been re-
ported that aldosterone is produced in the ventricles of the
failing human heart (41). Furthermore, it has been reported
that the aldosterone synthase gene is expressed in cardiac
tissue (42). We did not measure plasma renin activity or
aldosterone concentrations. However, aldosterone may be
produced in cardiac tissue, even if the plasma aldosterone
concentration is normal. Therefore, we believe that it is
important to inhibit aldosterone produced in cardiac tissue
by adding spironolactone to an ACE inhibitor in patients
with DCM.
Conclusions. The TDS, H/M, and WR, as determined by
123I-MIBG scintigraphy, were significantly improved after
six months of spironolactone treatment. In addition, LV
volume improved with spironolactone therapy. There was a
significant correlation between changes in the 123I-MIBG
scintigraphic findings and changes in the LVEDV with
spironolactone treatment. These findings indicate that long-
term spironolactone treatment can improve cardiac sympa-
thetic nerve activity and LV remodeling in patients with
DCM.
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